Home
Asthma & COPD

SAE Media Group proudly present their 10th annual Asthma and COPD conference taking place in Central London on Wednesday 2nd and Thursday 3rd April, 2014. 

This year’s event will focus on the cutting edge concepts driving the developments of asthma and COPD forward.


There is a growing demand for the next generation of inhaled combination products and novel therapeutics. This conference will enable delegates to gain valuable insight into the latest ground-breaking advances in the respiratory drug market. It will focus on the challenges and strategies to enhance patient outcomes, providing extensive knowledge from the key leading industry and academic experts.

The agenda will focuss on the treatment for exacerbations, clinical trial design and strategies for method enhancement, biomarkers and the utilisation of devices for Asthma and COPD. Key focus will be put on the anti-inflammatory developments in addition to the efficacy and toxicological issues relating to combination products.

Insight will be given on the current regulatory requirements and enable delegates to stay up to date with the guidelines.

A new session for 2014 will look at Cystic fibrosis, how does this relate to the developments within asthma and COPD?

 


 

FEATURED SPEAKERS

Christine  Ward

Christine Ward

Translational Medicine Lead, MedImmune
Nithyanandan Nagercoil

Nithyanandan Nagercoil

Senior Medical Assessor , MHRA
Noel  Snell

Noel Snell

Director of Research , British Lung Foundation

Anthony De Soyza

Clinical Senior Lecturer/Consultant, Newcastle University
Anthony  De Soyza

Brett Haumann

Vice President, Clinical Development and Operations , Theravance, Inc
Brett Haumann

Chris Compton

VP, Novartis Horsham Research Centre
Chris Compton

Christine Ward

Translational Medicine Lead, MedImmune
Christine  Ward

Ewan Walters

Medical Director, Teva UK Ltd
Ewan Walters

Fan Chung

Professor of Respiratory , National Heart and Lung Institute Imperial College London
Fan Chung

Jan-Anders Karlsson

CEO , verona pharma.
Jan-Anders Karlsson

John Warren

Director, Medicines Assessment
John Warren

Jørgen Vestbo

Professor of Respiratory Medicine, Hvidovre Hospital University of Copenhagen
Jørgen Vestbo

Matthew Catley

Team Leader RIA, AstraZeneca
Matthew Catley

Nicolas Touchot

Consultant , Therachallenges
Nicolas  Touchot

Nithyanandan Nagercoil

Senior Medical Assessor , MHRA
Nithyanandan Nagercoil

Noel Snell

Director of Research , British Lung Foundation
Noel  Snell

Omar Usmani

Clinical Senior Lecturer and Consultant Physician , Imperial College Of Science And Medicine
Omar  Usmani

Paul Meunier

Executive Director, Inhaled Product Development , Theravance, Inc
Paul  Meunier

Paul Whittaker

Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre
Paul Whittaker

Peter Howarth

Professor of Allergy and Respiratory Medicine, University Of Southampton School Of Medicine
Peter Howarth

Phillip Monk

Chief Scientific Officer , Synairgen Ltd
Phillip Monk

Roy Chapple

Business Development Manager , 3M Healthcare Limited
Roy Chapple

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Jørgen Vestbo

Jørgen Vestbo, Professor of Respiratory Medicine, Hvidovre Hospital University of Copenhagen

clock

9:10

Eclipse Observational Study for COPD

Jørgen Vestbo

Jørgen Vestbo, Professor of Respiratory Medicine, Hvidovre Hospital University of Copenhagen

• Assess how to measure inflammatory biomarkers to enhance patient outcomes
• Review the monitoring of patients over a 3 year period, and how this links to biomarkers with clinical outcomes
• What can we infer for treatment – what can we learn from biomarkers to enhance clinical trial outcomes

clock

9:50

Assessing potential new respiratory developments for market penetration

• TD-4208, an inhaled once-daily dosed Long-Acting Muscarinic Antagonist (LAMA) for the treatment of COPD                                                                                                                                                                                
• TD-5959/GSK-081, a multivalent Muscarinic Antagonist Beta2 Agonist (MABA) for the treatment of COPD

Brett Haumann

Brett Haumann, Vice President, Clinical Development and Operations , Theravance, Inc

Paul  Meunier

Paul Meunier, Executive Director, Inhaled Product Development , Theravance, Inc

clock

10:30

Morning Coffee

clock

11:00

Biomarker developments for respiratory drug assessment

Paul Whittaker

Paul Whittaker, Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre

• The heterogeneity of respiratory diseases poses a challenge for drug development
• Successful therapy will require the differential treatment of disease subgroups by defining the clinical subphenotype and matching the relevant drug(s) to that subphenotype
• The identification of biomarkers to enable patient stratification and provide support for efficacy of novel compounds in early clinical trials will be a key part of this process
 

clock

11:40

Evaluating patient stratification to enhance clinical trial design

Matthew Catley

Matthew Catley, Team Leader RIA, AstraZeneca

• Asthma as a heterogenic disease
• Why patient stratification is essential to clinical success
• Lessons from anti-IL-5 and anti-IL-13
• Where do we stand with COPD?

 

clock

12:20

Networking Lunch and Round Table Discussions

  • How do we enable individual patients to receive targeted treatments?
  • Assessing inflammatory phenotypes and improving cost effectiveness
  • clock

    13:30

    Clinical Trial Effectiveness - Assessment of Asthma and COPD

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

    • Reviewing PK data for combination therapies
    • Assessing real life studies for practicalities
    • Computerised management for GPs in Asthma and COPD
    • Evaluating the burden of disease model

    clock

    14:10

    Inhalation devices - evolution or revolution to address patient, health care professional and payor needs?

    Roy Chapple

    Roy Chapple, Business Development Manager , 3M Healthcare Limited

  • Past, present and near future of inhalation devices
  • What's the problem? Recent 3M research to understand current issues and future needs of patients, health care professionals and payors.
  • Evolution or revolution?
  • clock

    14:50

    Afternoon tea

    clock

    15:20

    Enhancing drug delivery through devices for Asthma and COPD

    Omar  Usmani

    Omar Usmani , Clinical Senior Lecturer and Consultant Physician , Imperial College Of Science And Medicine


     
    • Reviewing clinical device equivalence for safety and performance enhancement 
    • What are the revolutionary advancements in respiratory assessment 
    • MDI’s and DPI’s delivery of devices – what are the next generation of devices for inhaled respiratory medicines

    clock

    16:00

    Making the National Institute for Health Research infrastructure work for Pharma

    Anthony  De Soyza

    Anthony De Soyza, Clinical Senior Lecturer/Consultant, Newcastle University

  • Understanding what makes the UK an attractive destination for delivering trials
  • How the NIHR Respiratory speciality group has worked to aid Pharma
  • How evidence fror incorporation into
  • clock

    16:40

    DISCUSSION PANEL

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

    Anthony  De Soyza

    Anthony De Soyza, Clinical Senior Lecturer/Consultant, Newcastle University

    Roy Chapple

    Roy Chapple, Business Development Manager , 3M Healthcare Limited

    Nicolas  Touchot

    Nicolas Touchot , Consultant , Therachallenges

    clock

    17:20

    Chairman's Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Noel  Snell

    Noel Snell, Director of Research , British Lung Foundation

    clock

    9:10

    U-BIOPRED Observational Study for Asthma


    • Reviewing the history and set-up of U-BIOPRED
    • Assessing the protocol and plans for the future
    • Insight into the clinical academic initial data from the study
    • Industry perspective- How could this collaboration make for a beneficial output?

    Noel  Snell

    Noel Snell, Director of Research , British Lung Foundation

    Fan Chung

    Fan Chung, Professor of Respiratory , National Heart and Lung Institute Imperial College London


    • Reviewing the history and set-up of U-BIOPRED
    • Assessing the protocol and plans for the future
    • Insight into the clinical academic initial data from the study
    • Industry perspective- How could this collaboration make for a beneficial output?

    Chris Compton

    Chris Compton, VP, Novartis Horsham Research Centre


    • Reviewing the history and set-up of U-BIOPRED
    • Assessing the protocol and plans for the future
    • Insight into the clinical academic initial data from the study
    • Industry perspective- How could this collaboration make for a beneficial output?

    Peter Howarth

    Peter Howarth, Professor of Allergy and Respiratory Medicine, University Of Southampton School Of Medicine

    clock

    10:40

    Morning Coffee

    clock

    11:10

    Regulatory perspectives in the clinical development of fixed dose combination inhaled drugs

    Nithyanandan Nagercoil

    Nithyanandan Nagercoil , Senior Medical Assessor , MHRA

  • Guidelines & its impact on the clinical development plan
  • Scientific Advice during development
  • Issues during Assessment
  • clock

    11:50

    Discussion Panel


     • Assessing the current development stage of Asthma and COPD guidelines and reviewing the specific guidance that is out for consultation
    • Evaluating fixed-dose combinations and long-term cardiovascular safety for inhaled drugs
    • What are exacerbations and are they a good choice of primary end-point?

    Nithyanandan Nagercoil

    Nithyanandan Nagercoil , Senior Medical Assessor , MHRA

    John Warren

    John Warren, Director, Medicines Assessment

    Christine  Ward

    Christine Ward , Translational Medicine Lead, MedImmune

    clock

    12:30

    Networking Lunch and Road Table Discussions

  • Assessing exacerbations - How can we ensure better disease control?
  • What are the synergies between Asthma, COPD and Cystic Fibrosis? 
  • clock

    13:30

    Moving forward in Respiratory - Market Access

    Nicolas  Touchot

    Nicolas Touchot , Consultant , Therachallenges

    • Identifying  Payer Value Elements in COPD and Asthma
    • Addressing potential Payer Value uncertainties
    • Using Market Access to competitive advantage

    clock

    14:10

    KEYNOTE ADDRESS

    Christine  Ward

    Christine Ward , Translational Medicine Lead, MedImmune


    • Ensuring better disease control by stopping inflammation caused by the virus 
    • Understanding the comparison and contrast of postganglionic fibre receptors
    • Reviewing the use of mAbs to treat severe asthma and inflammation 
    • Assessing what the translational model issues are for exacerbations using computational models for potential disease progression 

    clock

    14:50

    Afternoon Tea

    clock

    15:20

    Development of Antivirals for the treatment/prevention of Virus Induced Exacerbations of Asthma and COPD

    Phillip Monk

    Phillip Monk, Chief Scientific Officer , Synairgen Ltd

    • Unmet clinical need
    • Target mechanisms: pathogen or host?
    • Therapies in Development
    • Future therapeutic options

    clock

    16:00

    RPL554 as a novel dual PDE3 and 4 inhibitor for the treatment of Asthma and COPD

    Jan-Anders Karlsson

    Jan-Anders Karlsson, CEO , verona pharma.

    • COPD is one of the most common chronic diseases in the world, and the prevalence is increasing
    • COPD is one of the most common causes of hospitalization in UK
    • More effective treatments are needed to reduce exacerbations and hospitalizations
    • RPL554 is an effective bronchodilator with anti-inflammatory properties
    • RPL554 is a novel, inhaled treatment for patients with severe COPD, currently in Phase 2 clinical trials

    clock

    16:40

    Chairman’s Closing Remarks and Close of Day Two


    Clinical Senior Lecturer/Consultant
    Newcastle University
    Vice President, Clinical Development and Operations
    Theravance, Inc
    VP
    Novartis Horsham Research Centre
    Translational Medicine Lead
    MedImmune
    Medical Director
    Teva UK Ltd
    Professor of Respiratory
    National Heart and Lung Institute Imperial College London
    CEO
    verona pharma.
    Director
    Medicines Assessment
    Professor of Respiratory Medicine
    Hvidovre Hospital University of Copenhagen
    Team Leader RIA
    AstraZeneca
    Consultant
    Therachallenges
    Senior Medical Assessor
    MHRA
    Director of Research
    British Lung Foundation
    Clinical Senior Lecturer and Consultant Physician
    Imperial College Of Science And Medicine
    Executive Director, Inhaled Product Development
    Theravance, Inc
    Unit Head for Pre-Clinical Biomarkers
    Novartis Horsham Research Centre
    Professor of Allergy and Respiratory Medicine
    University Of Southampton School Of Medicine
    Chief Scientific Officer
    Synairgen Ltd
    Business Development Manager
    3M Healthcare Limited

    INTERVIEW WITH CHRISTINE WARD, PRINCIPLE SCIENTIST, TRANSLATIONAL MEDICINE-RIA, MEDIMMUNE

    Download

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.